DelveInsight’s “Cerebral Palsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cerebral Palsy, historical and forecasted epidemiology as well as the Cerebral Palsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Cerebral Palsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cerebral Palsy Market Forecast
Some of the key facts of the Cerebral Palsy Market Report:
The Cerebral Palsy market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
The cerebral palsy market is projected to experience steady growth, with a strong compound annual growth rate (CAGR) expected from 2024 to 2034. This growth across the 7MM is fueled by the launch of new therapies like MYOBLOC and UDI-001, as well as improvements in genetic testing and diagnostic methods.
According to DelveInsight’s epidemiology model, there were roughly 1.9 million prevalent cases of cerebral palsy in the 7MM in 2023, including about 1.8 million diagnosed cases. This figure is expected to increase during the study period from 2020 to 2034.
In 2023, the US reported the largest number of diagnosed cerebral palsy cases within the 7MM, totaling nearly 932 thousand, which accounts for about 53% of all cases in these areas.
In 2023, the UK recorded the highest number of diagnosed cerebral palsy cases among the EU4 and the UK, with about 142 thousand cases, followed closely by Germany with nearly 134 thousand cases. In contrast, Italy had the fewest diagnosed cases, totaling around 105 thousand.
In 2023, Japan recorded around 221 thousand cases of cerebral palsy, and this figure is projected to change by 2034.
In 2023, the breakdown of type-specific cerebral palsy cases in the US included about 755 thousand spastic cases, 26 thousand dyskinetic cases, 24 thousand ataxic cases, 26 thousand hypotonic cases, and nearly 151 thousand cases classified as other or mixed types. These figures are expected to increase over the study period.
Key Cerebral Palsy Companies: Ipsen, Abbvie (Allergan), Supernus Pharmaceuticals, Neurocrine Biosciences, Teva Pharmaceuticals, Bundang CHA Hospital, Jazz Pharmaceuticals, Stanford University, Teva Branded Pharmaceutical, Merz Pharmaceuticals GmbH, Rohto Pharmaceutical Co., Ltd., Shionogi, and others
Key Cerebral Palsy Therapies: DYSPORT (abobotulinumtoxin A), Botox (Onabotulinum toxin A), MYOBLOC (RimabotulinumtoxinB), VALBENAZINE, AUSTEDO, Erythropoietin, Sativex, Botulinum Toxin type B, TEV-50717, IncobotulinumtoxinA, UDI-001, Oral Glycopyrrolate Liquid, and others
The Cerebral Palsy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cerebral Palsy pipeline products will significantly revolutionize the Cerebral Palsy market dynamics.
Cerebral Palsy Overview
Cerebral Palsy comprises a collection of conditions impacting movement, muscle tone, and posture. The condition arises from damage to the developing brain, typically occurring before birth, which can affect motor function control. Those affected may experience challenges with both voluntary and involuntary movements, leading to unsteady or lax motions.
Get a Free sample for the Cerebral Palsy Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/cerebral-palsy-market
Cerebral Palsy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Cerebral Palsy Epidemiology Segmentation:
The Cerebral Palsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Cerebral Palsy
Prevalent Cases of Cerebral Palsy by severity
Gender-specific Prevalence of Cerebral Palsy
Diagnosed Cases of Episodic and Chronic Cerebral Palsy
Download the report to understand which factors are driving Cerebral Palsy epidemiology trends @ Cerebral Palsy Epidemiology Forecast
Cerebral Palsy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cerebral Palsy market or expected to get launched during the study period. The analysis covers Cerebral Palsy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cerebral Palsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Cerebral Palsy Therapies and Key Companies
DYSPORT (abobotulinumtoxin A): Ipsen
Botox (Onabotulinum toxin A): Abbvie (Allergan)
MYOBLOC (RimabotulinumtoxinB): Supernus Pharmaceuticals
VALBENAZINE: Neurocrine Biosciences
AUSTEDO: Teva Pharmaceuticals
Erythropoietin: Bundang CHA Hospital
Sativex: Jazz Pharmaceuticals
Botulinum Toxin type B: Stanford University
TEV-50717: Teva Branded Pharmaceutical
IncobotulinumtoxinA: Merz Pharmaceuticals GmbH
UDI-001: Rohto Pharmaceutical Co., Ltd.
Oral Glycopyrrolate Liquid: Shionogi
Discover more about therapies set to grab major Cerebral Palsy market share @ Cerebral Palsy Treatment Landscape
Cerebral Palsy Market Strengths
Stem cell therapy is a novel treatment for Cerebral Palsy compared with symptomatic standard care has shown a significant positive effect on gross motor function. Short term safety is present, and further investigations are ongoing.
Cerebral Palsy Market Opportunities
Due to increasingly compelling evidence that Cerebral Palsy can have a genetic component, studies are testing interventions such as deep brain stimulation (DBS) and personalized medicine for the treatment of patients with Cerebral Palsy.
Scope of the Cerebral Palsy Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Cerebral Palsy Therapeutic Assessment: Cerebral Palsy current marketed and Cerebral Palsy emerging therapies
Cerebral Palsy Market Dynamics: Cerebral Palsy market drivers and Cerebral Palsy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Cerebral Palsy Unmet Needs, KOL’s views, Analyst’s views, Cerebral Palsy Market Access and Reimbursement
To know more about Cerebral Palsy companies working in the treatment market, visit @ Cerebral Palsy Clinical Trials and Therapeutic Assessment
Table of Contents
1. Cerebral Palsy Market Report Introduction
2. Executive Summary for Cerebral Palsy
3. SWOT analysis of Cerebral Palsy
4. Cerebral Palsy Patient Share (%) Overview at a Glance
5. Cerebral Palsy Market Overview at a Glance
6. Cerebral Palsy Disease Background and Overview
7. Cerebral Palsy Epidemiology and Patient Population
8. Country-Specific Patient Population of Cerebral Palsy
9. Cerebral Palsy Current Treatment and Medical Practices
10. Cerebral Palsy Unmet Needs
11. Cerebral Palsy Emerging Therapies
12. Cerebral Palsy Market Outlook
13. Country-Wise Cerebral Palsy Market Analysis (2020–2034)
14. Cerebral Palsy Market Access and Reimbursement of Therapies
15. Cerebral Palsy Market Drivers
16. Cerebral Palsy Market Barriers
17. Cerebral Palsy Appendix
18. Cerebral Palsy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
